OpenAlex
PricingAboutJobs
Log inGet started
Work

RAS-targeted therapies: is the undruggable drugged?

HTML

Year: 2020
Type: review
Source: Nature Reviews Drug Discovery
DOI: 10.1038/s41573-020-0068-6
Authors: Amanda R. Moore, Scott C. Rosenberg, Frank McCormick, Shiva Malek
Institutions: Genentech, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English

Topic: Protein Kinase Regulation and GTPase Signaling
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: Ras, KRAS, NRAS, HRAS, RAS inhibitors, KRAS G12C, RAS-driven cancers, combination therapy, Ras effector pathways, immune checkpoint inhibitors, T cell targeting, non-small cell lung cancer
SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute
Award: New Ways of Targeting K-Ras
OpenAlex ID: W3034504519
FWCI: 13.25
Cites: 279
Cited by: 1,283
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security